

EUROFINS BIOMNIS RESPONDS TO INCREASING DEMAND FOR EXOME SEQUENCING

Eurofins Biomnis, top European provider of specialised clinical pathology services, was first in line for the next generation of sequencer developed by its supplier Illumina, the leader in this segment. As demand for exome sequencing continues to grow, Eurofins Biomnis became the first private sector clinical lab in France to acquire the NextSeq 2000. This enables Eurofins Biomnis to further increase the availability of *whole exome* sequencing and thus enhance the care of patients with genetic diseases.

Eurofins Biomnis committed to responding to current challenges in genomic medicine

There are more than 7,000 rare genetic diseases in the world. The heterogeneity of their clinical forms makes diagnosis very difficult: in more than 50% of cases, it is not possible to obtain a diagnosis with conventional clinical biology approaches. The challenge is therefore medical but also financial, i.e. to avoid the multiplication of costly, sometimes redundant, analyses.

Eurofins Biomnis has responded to these challenges by developing a wealth of expertise in exome sequencing in recent years. From the end of 2016, the laboratory has been able to offer *whole exome sequencing*, a genomic technique which involves sequencing in a single step all the coding regions of the human genome (containing more than 85% of pathogenic mutations). In recognition of its expertise, the team of more than ten technicians, four scientific experts, four bioinformaticians and six clinical pathologists has seen demand for this analysis increase sharply. Between 2019 and 2020, for example, demand doubled.

Fulfilling requests and reporting test results as quickly as possible (turnaround time is currently 6 weeks) is one of the main priorities for Eurofins Biomnis. Exome sequencing improves the diagnosis of diseases of genetic origin and thus reduces errors to the benefit of patients.

A new tool to increase the availability of exome sequencing



Eurofins Biomnis clinical pathologists now have access to Illumina's new generation sequencer, the NextSeq 2000. This new equipment will allow laboratory teams to handle more samples while ensuring optimum turnaround times for results and the highest quality standards. With the NextSeq 2000 and the technical expertise of Illumina, Eurofins Biomnis can continue to innovate in this area. Making exome sequencing more available also means further improving the rate of diagnosis of these pathologies.

Eurofins Biomnis press contact

Wellcom Communications Agency
Gaëlle Ryouq, Héroïse Sintès
biomnis@wellcom.fr
(+33) 01 46 34 60 60

wellcom



About Eurofins Biomnis

European leader in the sector of specialised clinical pathology, Eurofins Biomnis carries out over 32,000 analyses per day from a range of over 2,500 available tests, including highly specialised tests. Founded in 1897 by Marcel Mérieux, Eurofins Biomnis is the leader in specialised clinical pathology in France. It has maintained this leading position through continuous technological innovation and investment, particularly in areas such as women's pathology, oncology and personalised medicine, as well as chromosomal and molecular genetics. With 120 years of expertise and innovation in the service of clinical pathology, Eurofins Biomnis forms the core of the Clinical Diagnostics division of the Eurofins Group in Europe and is actively expanding in worldwide markets. www.eurofins-biomnis.com

About Eurofins - the global leader in bio-analysis

With over **50,000 staff** across a network of more than **800 laboratories** in over **50 countries**, Eurofins' companies offer a portfolio of over **200,000 analytical methods**.

Eurofins Shares are listed on Euronext Paris Stock Exchange.